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Abstract
Drugs including analgesics need a delivery system to deliver it to the site of action upon 
administration. Delivery can be achieved using various types of dosage forms includ‐
ing tablets, capsules, creams, ointments, liquids, aerosols, injections, and suppositories. 
Conventional drug delivery systems provide immediate release of the analgesics with‐
out controlling the rate of release. A number of doses must be given daily in order to 
achieve and maintain effective plasma concentrations. Frequent administration causes 
fluctuations in plasma levels of the drug. The drug plasma levels could fall below the 
minimum effective concentration and can also exceed the minimum toxic concentra‐
tion. The purposes behind controlling the drug delivery for analgesic are to achieve 
more effective therapies while eliminating the potential for both under and overdos‐
ing. The need for fewer administrations for “no pain” maintenance and with optimal 
use of the drug in question is to avoid adverse effect, and to increased patient compli‐
ance. Modified‐release analgesics have enabled patients to better maintain pain control 
by convenient dosing intervals and sustained blood concentrations. The differences 
between available modified‐release products are half‐life, cost, and formulation and 
drug‐release properties.
Keywords: analgesic, pain management, modified drug delivery system, specialty product 
and polymer
1. Introduction
Analgesics are medicines that relieve pain or in other words they are drugs that are used 
to provide pain relief. When we browse the topic on analgesics we will also come across 
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the term narcotic as first analgesics as they were narcotics, and their derivatives and 
 analogs were  chemically based on the morphine molecule [1]. Additionally, analgesics 
may include  nonsteroidal anti‐inflammatory drugs (NSAIDs) and paracetamol (acetamin‐
ophen). Practically, the term may also include others like tricyclic antidepressants and 
substances such as gabapentin, although they are not commonly classified as analgesics 
[1]. It should be well differentiated that usually analgesics give symptomatic relief, but 
have no effect on the body condition, although NSAIDs are beneficial in both reducing 
pain and inflammation.
2. Pain
Why god created pain? To the author, the answer to this question explains the term 
“ productive pain” which has been described in literatures as a warning on the occurring 
of injury in the body. This pain will guide the person to seek treatment, and this pain will 
also facilitate  diagnosis. “Nonproductive” pain by definition serves no purpose either as a 
warning or diagnostic tool. It is important for us to understand pain pathophysiology for 
 management purpose.
Pain syndromes may be different, but their sensory pathways are the same. It starts from the 
affected organ and the message flow to the brain for interpretation. The pharmacological path 
of analgesics’ action is by working at the level of the nerves, they work by either blocking the 
signal originating from the peripheral nervous system, or can work centrally by distorting the 
interpretation by the central nervous system.
Practitioners’ selection of an appropriate analgesic is first based on the type of pain and 
 severity and then the knowledge of risk and extra benefit and indirectly considering  existing 
risk‐benefit of a particular drug. The decision will also depend on the knowledge on the 
classes of drugs, and their adverse effect. Text books have divided pain into two classes, acute 
and chronic. In selecting the analgesic to be used, severity and predicted survival of patient 
must also be considered as a selection criteria [2].
2.1. Acute pain
Acute pain duration is self‐limiting and this includes postoperative pain, pain of injury, 
and childbirth. This type of pain is foreseen to be short in duration so the treatment using 
narcotic pain killer is considered to be safe as there will not be long‐term addiction prob‐
lem on using narcotics. Using NSAIDs will also be beneficial as it allows fluctuation of 
dose but with limiting concern on the risk of ulcers. For both categories of painkillers, their 
doses may be adjusted based on observation of healing rate, changing doses from high to 
low doses, and from narcotic analgesics to nonnarcotics as required. In severe pain, it is the 
rule of thumb that patients should not be subject to the return of pain so painkiller needs 
to be dosed  adequately to ensure that pain is at least tolerable to avoid the occurrence of 
anxiety, usually after the return of pain [3]. Generally, in pain management, painkiller 
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should never be dosed on as needed basis, but should be administered often enough to 
assure effective plasma level (this could be warrantied with the use of a sustained release 
preparation).
2.2. Chronic pain
Chronic pain is defined as pain lasting over 3 months and severe enough to have effect on 
body function. This condition is more difficult to treat, as the expected side effects of the 
drug are more difficult to manage because of the long‐term exposure to the drug. There 
will be  addiction potential for those who are on narcotic analgesics which can exacerbate 
to  respiratory  depression and constipation. For those using NSAIDs, the risk of gastric 
ulcers is evident. Drugs with narcotic agonist‐antagonist properties such as buprenorphine, 
 nalbuphine,  pentazocine, or the COX‐2 inhibitors, such as celecoxib and rofecoxib, which 
reduces the  common side effect, are still not recommended for long‐term management of 
severe pain. Usually,  practitioners  following the guidelines for chronic pain management 
will recommend a combination of drug therapy to suite the lifestyle and other treatment 
modalities [2]. Modification of the delivery system of the drug for the purpose of long‐term 
treatment is also beneficial [4].
3. Group of analgesic drug
3.1. Narcotic analgesics
Narcotic analgesics are all derived from opium. They include morphine, codeine, and a  number 
of semisynthetics including meperidine (Demerol), propoxyphene (Darvon)  tramadol, and a 
few others. Different narcotic analgesics may vary in their potency, but all of them are  effective 
in the treatment of visceral pain. Generally, their adverse effects are very much dose‐related 
as they are all addictive in nature [5]. These category of drug are regulated by the authorities 
as they are open for abuse, usually they are controlled under the nation’s laws.
3.2. NSAIDs
NSAIDs are available as effective analgesics even at low doses where there is no antiinflama‐
tory effect. They are in the form of various chemical types although they have demonstrated 
 similar pharmacological effect in reducing pain. They may even possess similar side effects. 
They are mostly provided in the form of oral dosage although some may be in the form of 
injection [6].
Paracetamol, or acetaminophen as Americans call it, is a nonnarcotic analgesic with no 
 antiinflammatory properties. It is the most popular analgesic which is appropriate for mild to 
moderate pain. It is well tolerated in normal recommended doses but it may have significant 
liver toxicity at high doses. Clinically, paracetamol has been considered the first choice for 
mild pain as it is considered to be very safe at therapeutic doses.
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4. Various dosage form of analgesic and their mode of actions  
and limitations
4.1. Conventional dosage forms of analgesics
Conventional dosage forms of analgesic are the same as any conventional dosage form 
of  general pharmaceuticals. Dosage which is synonymous with unit doses, means 
 pharmaceutical drug products in the form found commercially in the market with a spe‐
cific mixture of active ingredients and inactive excipients in specific form or configuration. 
Dosage forms come in several types, depending on the route of administration. The gen‐
eral forms include liquid, solid, and semisolid forms. Specifically, conventional dosage 
forms are solutions or suspensions for injection, pill, tablet, capsule, and syrup. Clearly, 
the administrative route of the drug is dependent on the dosage form of the substance. 
An oral solid dosage form is the solid form of a dose of a chemical compound used as 
a drug or medication intended for oral consumption. More than one dosage forms may 
exist for a single particular drug. This is due to the fact that different clinical conditions 
may need different routes of administration [8]. For example, where there is a condition 
of nausea or vomiting, it may be difficult to use an oral dosage form. Such condition may 
warrant an alternative route such as injection or rectal route. Dedicated specific route may 
be a requirement for certain kinds of drugs, as there may be issues with various factors 
like chemical stability or pharmacokinetics. A good example is the analgesic paracetamol, 
it exist in a number of dosage form, that is, tablet, capsule, syrup, suppository, and injec‐
tion (Table 1).
Type of pain killer in the market Common dosage form available
1. Paracetamol (acetaminophen) Tablets, solution, suspension, suppository, 
injection
2. Paracetamol with codiene Tablets, solution, suspension
3. Celecoxib Capsules
4. Diclofenac Tablets, capsules, gel (local application)
5. Fentanyl Tablets, capsules, *transdermal patch
6. Hydrocodone Tablets, elixer
7. Hydrocodone with paracetamol Tablets, elixer
8. Hydromorphone Tablets, injection, suppositories, liquid
9. Ibuprofen Tablets, solution, suspension
10. Meloxicam Tablets, oral suspension
11. Methadone Tablets, oral solution, oral concentrate, 
injection
12. **Methylprednisolone Tablets, injection
13. Milnacipran Tablets, injection
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5. Various new dosage forms, making their way to the market
5.1. Research in the development of new delivery system with existing analgesic
Development of modified release painkiller is a popular research. This type of research looks 
into the development of techniques and evaluation of the modified forms used in the man‐
agement of chronic pain in comparison with existing dosage form [7]. The realization on the 
importance of pain management and the treatment of pain has initiated more research in this 
area among healthcare researchers. Modified‐release products have enabled patients to better 
maintain pain control due to convenient dosing intervals and sustained blood concentrations. 
With the above statements, it is evidenced that development of modified release is very much 
needed for pain management drug, so as to be very effective and to prolong the effect for 
more effective pain management [7].
All drugs need a delivery system to deliver it to the site of action upon administration. Delivery 
of the drugs can be achieved using various types of dosage forms including tablets, capsules, 
creams, ointments, liquids, aerosols, injections, and suppositories. These conventional drug 
delivery systems provide immediate release of the drug without controlling the rate or drug 
release. A number of doses given daily in order to achieve and maintain therapeutic level to 
achieve effective plasma concentrations cause fluctuations in plasma levels of the drug [8–10] 
and drug plasma levels could fall below the minimum effective concentration and can also 
exceed the minimum toxic concentration (Figure 1).
5.2. The various types of modified release preparation possible for analgesics delivery
The purpose behind controlling the drug delivery for analgesic are to achieve more effective 
therapies while eliminating the potential for both under‐ and overdosing of analgesic.
Maintenance of analgesic levels within a desired range to combat pain is indirectly combat‐
ing stress to the patient. The need for fewer administrations of analgesic or optimal use of 
Type of pain killer in the market Common dosage form available
14. Morphine Tablets, injection
15. Naproxen Tablets, *delayed‐release enteric coated 
tablets, suspension
16. Oxycodone Tablets, oral concentrate, oral solution
17. Oxycodone with paracetamol Tablets
18. **Prednisone Tablets, solution
19. Sumatriptan Injection, tablets, *nasal spray
*Analgesic specialty products.
**Steroids as adjuvant to analgesic, OK.
Table 1. Some of the analgesic and their dosage form available in the market.
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 analgesic toward “no pain” maintenance is to avoid adverse side effect and indirectly to 
increase patient compliance in their pain management [8].
5.2.1. The polymeric delivery system: polymers in controlled drug delivery
The use of various polymers in controlled drug delivery is very popular among formula‐
tion researchers. These polymers can be natural or synthetic in nature. Different polymer is 
combined with a drug in such a way that the active agent is released from the material in a 
predesigned manner. The release of the active agent may be constant over a long period or it 
may be cyclic over a long period or it may be triggered by the environment or other external 
events [9].
Polymer can be used to encapsulate drug molecules for the purpose of sustaining the release 
and extending the availability of the drug so that dosage administration frequency can be 
reduced while maintaining the plasma level steady state. A good example would be the sus‐
tenance of release preparation of diclofenac sodium for oral administration [8].
Polymer can also be used in protecting the drug from the environment in order to target the 
delivery of the drug to certain side of the body. A very simple targeting is the delivery of weak 
base drug to the small intestine where most of this type of drug is acid labile. So the polymer 
is used as a protective shield. This can be a pH‐sensitive polymer where in acidic environment 
it is very stable and will disintegrate in basic environment.
Characteristics of polymer may be engineered to the advantage in the development of a drug 
delivery system. A mucoadhesive polymer which can stick to the mucosa can be used to encap‐
sulate drug and attach to the mucosa and sustain the release of the drug it encapsulates. A biode‐
gradable polymer can be used to encapsulate drug for slow release as the polymer degrades. A 
pH‐sensitive polymer can be used to target the release of drug either in acidic or basic environ‐
ment. Combining all these characteristic, a researcher can even deliver a drug which currently 
can only be delivered by parenteral route, using the enthrall route. Logically, the drug can have 
an outer encapsulation with a pH‐sensitive polymer which can save it from the acidic environ‐
ment in the stomach and can have a mucoadhesive polymer inner encapsulation for it to stick 
to the small intestine lining and to release the drug direct across the membrane into the blood.
Figure 1. The conventional four times daily oral doses of diclofenac sodium (25 mg) plasma level compared to a daily 
doses sustained release formulation (100 mg) plasma level.
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The vast uses of polymer in the gastrointestinal, enthrall, or oral drug delivery system do 
not limit the same polymer to be used in other route of dosage administration. Several 
polymers in the form of nano size particles are used to deliver drug as an intravenous 
 dosage form [11]. Researchers are also looking into various polymers which can act as a 
depot for big dose administration of drug through implantation in the  subcutaneous 
area for cases of difficult patient compliance such as delivery of antipsychotics and 
 cancer drugs.
Some of the synthetic materials that are currently being used or studied for controlled drug 
delivery are as depicted in Table 2.
Polymer are sometimes crudely extracted from natural resources be it from animals or from 
plants. Such natural materials are depicted in Table 3.
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5.3. Controlled‐release mechanisms in the case of using polymer as a drug delivery system
There are three primary mechanisms by which active agents can be released from a 
 delivery system: diffusion, degradation, and swelling followed by diffusion. Any or all of 
these  mechanisms may occur in a given release system [12]. We can easily understand this 
 mechanism through Figures 2–8.
Polymer Polymer structure
Poly(vinyl alcohol).
(C
2
H
4
O)x
Poly(acrylic acid).
(C
3
H
4
O
2
)
n
Polyacrylamide.
(C
3
H
5
NO)
n
Poly(ethylene‐co‐vinyl acetate).
(C
2
H
4
)
n
(C
4
H
6
O
2
)
m
Poly(ethylene glycol).
C
2n
H
4n+2
O
n+1
Poly(methacrylic acid).
(C
4
H
6
O
2
)
n
Table 2. Example of synthetic polymer available in the market.
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Material Illustration Structure (if available)
Gelatin
Carrageenan
Chitosan
Arabic gum
Tamarind seed 
gum
Hibiscus 
esculentus gum
Table 3. Example of natural polymer used in drug delivery research.
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Figure 2. Analgesic diffusing out from a matrix of polymer in a sustain release model.
Figure 3. A dermal patch model illustrating the diffusion analgesic from a dermal path polymer matrix.
Figure 4. Analgesic delivery system by swelling of polymer acting as drug reservoir.
Figure 5. Analgesic delivery system by swelling of the polymer matrix encapsulating the drug.
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6. Transdermal drug delivery
Transdermal delivery patch usually consists of a reservoir of drug on a protective backing 
layer, a rate‐limiting release membrane, and an adhesive layer to attach the patch to the skin. 
The physicochemical of the drug suitable for transdermal delivery includes low molecular 
Figure 8. Surface eroding biodegradable polymeric delivery system.
Figure 6. Drug delivery from environmental sensitive release system.
Figure 7. Bulk eroding biodegradable polymeric delivery system.
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weight (<500 daltons), big molecules will have difficulty in penetrating the stratum corneum 
of the skin, high potency drug, water solubility (to facilitate movement of the drug out of the 
reservoir and to allow passage through the epidermal and dermal layers of the skin), and 
lipid solubility (to permit penetration of the stratum corneum of the skin). Fentanyl, a syn‐
thetic opioid agonist, is delivered by transdermal patch. For transdermal drug delivery, the 
penetration of the drug through the skin constitutes an additional series of diffusional and 
active transport steps [13].
The skin functions to maintain homeostasis of the body through temperature regulation, 
protection of underlying tissues, control water loss, rich sensory receptors, synthesizing of 
certain body chemicals, and excretion of wastes by sweating. The skin is made up of an outer 
epidermis and a dermis, followed by underlying tissue of subcutaneous layer (Figure 9). The 
epidermis is made up of stratified squamous epithelium and lacks blood vessels and it forms 
good barrier to protect the underlying tissue and blood capillaries. This becomes an impor‐
tant issue in the development of transdermal dosage forms so as to deliver the drug across 
the stratified layers [14].
Drug in the transdermal dosage form are generally poorly absorbed, but in the positive man‐
ner this will form a dosage form with a very controlled depot effect. It is an ideal dosage form 
for analgesics but the common problem is that the drug may cause focal irritation. Currently, 
in the market transdermal drug delivery for systemic effects is limited to very few drugs, 
those having low molecular weights and high lipophilicity. Transdermal drug delivery sys‐
tem may be optimized for controlled release of the drug for a steady plasma profile. This 
will reduced systemic side effects and may also improve efficacy of the analgesic drug. It is 
user‐friendly, convenient, painless, and offer prolong dosing and all this will contribute to 
improved compliance [15]. Examples of such dosage forms available in the market are the 
morphine and sufentanil patches.
Normally, transdermal system in a patch form is made up of an outer covering which forms 
the barrier, a drug reservoir, a control membrane to control the release of the drug, a contact 
adhesive applied to some or all parts of the system to make it stick to the skin surface, and a 
covering protective layer that is removed before the patch is applied (Figure 10a). The drug 
reservoir is sometimes replaced with a matrix of polymer where the drug is encapsulated 
(Figure 10b).
Figure 9. The barriers in epidermis which limit the penetration drug through the skin.
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Researchers can be creative in the development of transdermal delivery system for analgesics. 
The followings are a few creative ideas on delivery of drug using various dermal patches with 
each having its own technique of engineering.
6.1. Iontophoresis
An active state of transdermal technologies uses low voltage electrical current to drive 
charged drugs through the skin. This will enable charged particles of drugs to move across 
the stratum corneum. Each iontophoresis patch is a device consisting of a housing which 
contains the battery and related electronics, two polymeric reservoirs for anode and cathode, 
and skin adhesive. Only one of the polymeric reservoirs contains the drug. The other may 
contain only pharmacologically inactive ingredients. Figure 11 depicts the iontophoresis 
system. The choices on whether the anode or the cathode contains the drug are dependent 
on the drug charge.
Figure 10. (a) The structure of a reservoir dermal patch. (b) Two types of structures for matrix dermal patch.
Figure 11. Iontophoresis patch illustration.
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The technique of iontophoresis has the potential to be expanded to deliver proteins and pep‐
tides. The current can be literally switched on and off and modified, also iontophoretic delivery 
enables rapid onset and offset, and drug delivery is highly controllable and programmable.
6.2. Electroporation
This transdermal drug delivery technique uses short electrical pulses of high voltage to create 
transient aqueous pores in the skin, in a variety of forms, temporarily to disrupt the stratum 
corneum and to allow drug in the reservoir or the polymeric matrix to cross the stratum cor‐
neum and then penetrate the blood vessel (Figure 12).
6.3. Sonophoresis
This transdermal drug delivery technique uses low‐frequency ultrasonic energy (15‐ second 
burst of ultrasound at 55 kHz) to disrupt the stratum corneum and to allow drug in the 
 reservoir or the polymeric matrix to cross the stratum corneum and then penetrate the blood 
vessel. Similar to the electroporation effect, the sound waves create cavitation bubbles in the 
tissue that disrupt the lipid bilayers of the cells of the stratum corneum creating microchan‐
nels. The ultrasound poration can increase the transport properties of the stratum corneum by 
100‐fold. Figure 13 illustrates the effect of sonophoresis.
6.4. Microneedle dermal patch
This transdermal patch technique makes use of microneedles, which are microscopic, just 
a few hundred microns in size. They can pierce the skin in a minimally invasive manner 
Figure 12. Temporary disruption of the bilipid membrane after electroporation. A: Normal arrangement of the bilipid 
membrane B: Bilipid membrane after electroporation C: Recovery of the Bilipid membrane after an interval.
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 without causing pain or injury [16]. A lot of research in the literature shows that this pierc‐
ing effect increases transdermal flux of large molecular weight compounds by many folds. 
There are two ways of utilizing the microneedles, one of the ways in which drug delivery is 
achieved is to coat the drug onto microneedle shafts and insert them into the skin where they 
deposit the drug. The second way is upon piercing skin they create microconduits across 
stratum corneum and this will provide a direct route for transport of drugs into the skin from 
the patch reservoir (Figure 14).
7. Nanoparticle delivery systems
Nanoparticle systems as drug carriers may also play a very important role in the deliv‐
ery of analgesics. The advantages of nanoparticles used as drug carriers include fast action 
of the nano formulation, high product stability, good loading capacity, both hydrophilic 
and hydrophobic substances can be given together in the same formulation, and various 
routes of administration can be utilized [11]. Analgesics in nanoparticulate systems would 
be transported and released in a controlled manner at the target area, depending on the 
environmental conditions. Analgesic nanoparticulate can have the following advantages: 
reducing the dose of the drug, some specialty formulation may allow analgesic drugs that 
normally do not cross the blood brain barrier to penetrate into the brain where this can 
reduce the peripheral side effects by lowering the amount needed to act directly on the 
central nervous system. The development of the analgesic‐loaded nanoparticulate systems 
Figure 13. Bubble formation after sonoporesis process, forming channel for drug penetration. A: Normal arrangement of 
the bilipid membrane B: Formation of bubbles in Bilipid membrane after sonoporesis.
Figure 14. Illustration of microneedle transdermal patch with drug reservoir.
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may represent a future challenge to achieve promising agents for regional drug delivery in 
pain management strategy.
Nanoparticles can also be solid or soft colloidal matrix‐like polymeric particles or 
 lipids. They can be drug carrier system such as liposomes. Other drug delivery sys‐
tems are based on using nanoparticles composed of biodegradable polymers, this has 
been explained in the earlier subsection on polymeric drug delivery system [17]. These 
 microparticles may consist of polymeric nanospheres in an oily reservoir or aqueous 
medium. It was shown in research that a numbers of analgesic drugs such as ibuprofen, 
flurbiprofen, and acetyl salicylic acid have been successfully delivered by entrapping in 
nanoparticles [18].
8. Multiphase liposomal drug delivery system
Liposome is a drug delivery system suitable for various routes of drug administration, i.e., 
oral, rectal, parenteral, and particularly local administration to the skin, eye, and mucous 
membranes [19]. Liposomes are microscopic phospholipid‐bilayered vesicles and they have 
the advantage in which they can be used to entrap both hydrophilic and lipophilic drug for 
delivery. Figure 15 illustrates the formation of liposome for drug delivery. Liposomes are 
generally administered by intravenous route but they are also developed for transdermal or 
subcutaneous implantation.
8.1. The concept of LipoSpray
Using the liposomal concept “LipoSpray” is an innovative idea in delivering an analge‐
sic in the form of liposomal suspension. The suspension is sprayed into the mouth and 
under the tongue. Liposomes penetrate the mucosal tissue of the mouth, and the drug is 
released from the liposome into the bloodstream, distributing the drug throughout the 
body in minutes.
This path bypasses the gastrointestinal (GI) track and bypasses the first‐pass effect of the liver. 
The analgesic in question would have a fast effect in pain management.
Figure 15. Various morphology of the polar and nonpolar arrangements in liposome and its formation.
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9. Basic research methodology in development of new drug delivery 
systems in delivering analgesics
This subchapter illustrates an example of research steps in the development of a drug 
 delivery system using nano technology. The steps illustrated in this section may be applicable 
to  certain extent in research toward the development of an analgesic drug special delivery 
 system. The techniques are not exhaustive and are just an example to guide the researchers.
9.1. Getting the delivery material (e.g., polymerization reaction to get the polymer)
At the beginning of the investigation, efforts should focus on the preparation of a polymeric 
system. There are two different types of polymerization reactions: addition  polymerization and 
condensation polymerization. Addition polymerization involves the use of a radical generating 
initiator which triggers polymerization reaction of monomers. Condensation  polymerization 
involves reaction of monomers containing reactive functional groups to form a polymer.
The FTIR and 1HNMR spectra need to be used to confirm the formation of the desired 
 polymer. Further attempts to synthesize larger amount of the polymer for characterization 
studies need to be done.
One important characterization is the determination of molecular weight. Gel permeation 
chromatography (GPC) can be used to analyze molecular weight of the polymer. A solution 
of 1 mg/1 ml of the polymer in tetrahydrofurane needs to be prepared and analyzed by GPC.
9.2. Determination of polymer stability
Another important criterion is to determine the in vitro degradation of the polymer so as to 
ensure its stability as required. The in vitro degradation study can be carried out through 
 preparing polymeric devices and placing them in phosphate buffer solution for different peri‐
ods of time, and analyzing their wet and dry weight loss [20].
Scanning electron micrographs of sample need to be taken by scanning electron  microscope 
(SEM) to observe the erosion characteristics of the polymer. SEM is a technique for the 
 preparation of high resolution images from surface of different compounds. Electrons are 
used for imaging in scanning electron microscopes.
The differential scanning calorimetry (DSC) is also a requirement in the determination of the 
thermal stability of the polymeric system [21].
9.3. Cytotoxicity issues
If the polymer being optimized is a new polymer then it is important to establish the 
 cytotoxicity of the synthesized polymer to evaluate whether the polymer is appropriate for 
application in drug delivery systems or not. In other words, the synthesized polymer should 
be nontoxic to normal body cells and tissues, and cause minimum side effects at the site 
of action. There are different types of tests and assays for the evaluation of cytotoxicity of 
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 polymers, as well as drugs. Cell‐based assays are the most widely used methods for assessing 
cell toxicity effects of different polymers or drugs on a particular cell line.
9.4. Preparation of drug‐loaded polymeric system
Thin film hydration method can be one of the methods for the preparation of the drug‐loaded 
polymeric system. An example is by using a solution of 2 mg/ml of polymer in ethanol 
(10 ml) and mixed with a solution of 5 mg/ml model drug in ethanol (1 ml). After stirring for 
15  minutes at room temperature, the solvent needs to be evaporated by rotary evaporator. 
The  precipitant is then mixed with 20 ml distilled water. The mixture is then centrifuged at 
6000 rpm for 10 minutes. The supernatant is then taken for further analysis for entrapment 
characteristics of the drug in the polymer.
9.5. Determination of entrapment efficiency
In order to obtain the entrapment efficiency, the concentration of the free drug is to be 
 determined upon preparation of the entrapment, 1 ml of the supernatant is taken and diluted 
with 3 ml water, and the concentration of the drug is determined by high  performance liq‐
uid chromatography (HPLC). Entrapment efficiency is calculated by the following equation:
  EE ( % )  =  total drug − free drug  ________________ 
total drug × 100 (1)
9.6. Determination of polydispersity
The polydispersity index (PDI) is a reflection of the heterogeneity and a measure of the  distribution 
of molecular mass in a given polymer sample. PDI is calculated as the weight average molecular 
weight, divided by the number of average molecular weight. It indicates the distribution of indi‐
vidual molecular masses in a batch of polymers. PDI value of 1 reflects that the polymer is of the 
same size and indicates uniformity of the chain length. The  following equation denotes the PDI:
  PDI =  M 
w
  /  M 
n
 (2)
where M
w
 is the weight average molecular weight and M
n
 is the number average molecular 
weight.
9.7. Determination of size, size distribution, and zeta potential of nanoparticles
Scanning electron microscopy (SEM) and dynamic light scattering (DLS) can be used to 
determine the size of nanoparticle. DLS is used for determining the size distribution and zeta 
potential of nanoparticles as well. Dynamic light scattering, which is also known as photon 
correlation spectroscopy, is one of the most widely used methods for the determination of 
size, size distribution, and zeta potential of nanoparticles. This instrument works through 
radiation of a light beam into a particulate system with Brownian motion.
9.8. Determination of the thermal characteristic of the delivery system
Differential scanning calorimetry (DSC) technique is the most common thermal  analysis 
 equipment used in the determination of material in the delivery system. This primary 
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 technique directly assesses the uptake of heat energy during the fluctuation of temperature 
in order to specify any connection among temperature and physical properties of samples. 
Calorimetry is a suitable thermal analysis technique for qualifying the purity, the melting 
point, and the polymorphic forms of samples [21].
9.9. In vitro drug release study
Drug release from the polymeric system shall be studied to prove good delivery as  stipulated. 
Commonly, the in vitro dissolution of the drug from the formulation is done following the 
available compendium method where standard dissolution apparatus are recommended. 
Other methods include using dialysis method where the formulation prepared is placed in 
the dialysis bag. The dialysis bags are then placed in a bath shaker at the temperature of 
37°C and rotated at the rate of 100 rpm. Samples were collected at different time intervals 
and analyzed.
9.10. In vivo animal study
This is one of the stages for preclinical study on the new formulation which can also be a 
new type of polymer or material used [19]. The safety and efficacy of this formulation need 
to be established. Before starting the study, the animal ethic committee needs to be consulted 
to get approval to start the study. Most of the studies are to prove that the pharmacokinet‐
ics of the drug delivered is appropriate as stipulated. The ADME (Absorption, Distribution, 
Metabolism, and Excretion) of the drug delivered by the system is important at this stage, 
especially the absorption and distribution.
For the technique in determining the absorption and the distribution of the active in a 
formulation, a researcher may in his or her study use optical in vivo imaging technique 
for monitoring the distribution of the drug in question the proposed delivery system in 
comparison with the  conventional dosage form available. This technique is able to image 
the whole body of small animals and body cells. This technique includes both fluorescence 
in vivo imaging and fluorescence  microscopy, and a low‐light camera and proper filters 
were also used to collect fluorescence excitation and emission light from samples. In fluo‐
rescence microscopy, the objects of  imaging are cells, slides, or culture dishes, while the 
whole body of small animals is pictured with optical in vivo imaging system. However, 
in vivo imaging is technically a more challenging process, as the animal tissues are opaque 
or/and thick, therefore, they absorb scatters photons and generate strong autofluorescence. 
Furthermore, it is essential to apply an appropriate imaging probe, which provides biolog‐
ically stable distribution and  preferential  accumulation at the intended target site. Loading 
near‐infrared (NIR)  fluorophores with drug delivery agents would be a great opportunity 
to follow medicine distribution with optical in vivo imaging  system  without using specific 
conjugated antibodies. Near‐ infrared excitable fluorescent agents (NIR)  provided deep tis‐
sue penetration and low tissue autofluorescence.
Researcher performing the animal study should also take the opportunity to do plasma level 
drug monitoring, urine metabolite level, and histological studies on heart, lungs, kidneys, 
spleen, and the liver.
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9.11. The human bioavailability study
This is a regulatory requirement as to prove that the new system will make the drug avail‐
able as the conventional system. It indirectly also determines if the drug pharmacokinetic 
 parameters in human are the same as for the original available formulation. This is different 
from bioequivalence, which is used to evaluate the predictable in vivo biological equivalence 
of two proprietary preparations of a drug. Two pharmaceutical products are bioequivalent 
if they are pharmaceutically equivalent and their bioavailabilities after administration in the 
same dose are similar to such a degree that their effects, with respect to both efficacy and safety.
Bioavailability measures the extent of a drug reaching the systemic circulation and is there‐
fore available for action at the expected site. For most drugs that are taken orally, the drug 
is released in the gastrointestinal (GI) tract and arrives at their site of action via the systemic 
circulation. Plasma concentrations of the drug or its metabolite would provide a marker for the 
concentration at the site of action and a valid measure of bioavailability. The researcher needs 
to build a plasma blood concentration time curve to prove the release of the drug from the 
preparation and its absorption from the GI tract, but also other factors including presystemic 
metabolism, distribution, and elimination. Bioavailability is proven through the area under the 
blood drug concentration versus time curve (AUC), the maximum blood concentration (Cmax) and the time to reach maximum concentration (Tmax). Clearly, bioavailability studies of the new 
delivery systems compared to the conventional ones need to be done so as to be assured that 
the new delivery system is not inferior compared to the existing systems.
10. Concluding statements
Drug delivery system represents a vast, vital area of research and development of new analge‐
sic product. It is pertinent for analgesic as pain management needs the painkiller to be fast in 
action, prolong action, and reduce adverse or side effect. So development of specialty product 
using advance drug release system is the answer to the betterment of pain  management and 
the research on this area is not exhaustive. In this chapter, we have discussed the available con‐
ventional dosage forms and gave examples. We also based our discussions on ideas in research 
and development of various advance new delivery system such as polymeric delivery system, 
sustain release system, transdermal delivery system, and liposome.
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